Please contact Scott Hall at email@example.com or 202-463-5817.
Speaking at Cato on IP in the Trans-Pacific Partnership
Global Innovation Policy Center @globalIPcenter 11h
“Waiving drug companies' intellectual property rights risks setting a bad precedent for future investment in new drugs. And that risk may not be worth it without additional steps to meaningfully increase the availability of shots across the world.” https://t.co/UE6nqe8Cyb